Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

In vitro human model for individualized response to CFTR modulators

Award Number: R41HL130207
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/06/2016
PERIOD OF PERFORMANCE END DATE: 08/31/2018

Group Awards By:

View Award Description

In vitro human model for individualized response to CFTR modulators - ¿ DESCRIPTION (provided by applicant): The approval of the cystic fibrosis (CF) drug invocator for patients with the G551D mutation validates CFTR modulators for improving clinical outcomes in CF. For most CF patients (with F508del and other mutations), however, multi-drug combination therapy will likely be necessary, and sensitive biomarkers of augmented CFTR function in response to various agents will be needed. In vivo assays employed to date have not been predictive of efficacy; neither do they correlate well with individual patient improvement. The proposed project combines two recent advances by researchers at the University of Alabama at Birmingham (UAB) and the Massachusetts General Hospital (MGH) to produce a novel in vitro human cell biomarker that will predict CFTR function in individual patients: 1) methods which allow primary human epithelial cell cultures of nasal origin (HNE) to proliferate rapidly and to maintain an airway phenotype; and 2) a pioneer imaging technology (Micro- Optical Coherence Tomography [µOCT]) which permits simultaneous and co-localized quantification of multiple elements of airway function, including mucociliary transport, demonstrating reproducible anatomic differences between CF and normal human explants and functionally characterizing in situ fully-differentiated primary human bronchial epithelial cells (HBE) grown in culture. µOCT can also directly visualize dynamic differences between CF and wild-type tissues, simultaneously measuring collapsed airway surface liquid (ASL) height, reduced cilia beat frequency (CBF), delayed mucus transport (MCT), and increased mucus viscosity. Preclinical data indicate primary human airway cell cultures strongly predict ion transport efficacy of CFTR potentiators and correctors on a group wise basis. Progenra will work with UAB and MGH to develop and commercialize the novel HNE culture as an in vitro biomarker for CFTR function, employing µOCT for simultaneous detection of the markers. In Phase 1 the validity and utility of combining primary nasal cells with optimized and automated µOCT-based analysis of the functional microanatomy will be established as a tool to predict efficacy in individual patients. It will first be demonstrated that an automated µOCT imaging acquisition and analysis system can distinguish the functional microanatomy (i.e. ASL/PCL depth, CBF, MCT, and viscosity) of normal and CF differentiated HNE. It will then be ascertained whether HNE cells from twenty-five (25) G551D CF subjects enrolled in the GOAL study, an open-label observational trial of invocator, predict therapeutic response to invocator on an individual basis. In Phase II, the study will be expanded to ~200 patients and five different mutant CFTR genotypes. The ultimate commercial goal is to develop an experimental system that faithfully predicts the responses to various CFTR therapies on an individual basis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2016	PROGENRA, INC	277 GREAT VALLEY PKWY	MALVERN	PA	19355	CHESTER	USA	Cardiovascular Diseases Research	000	1	1/10/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $339,094 )
2016	2016	PROGENRA INC	271 GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Cardiovascular Diseases Research	000	1	9/2/2016	NEW	$339,094
														Subtotal = $339,094

Grand Total All Awards = $339,094

Top

All Categories

About

Search

Reports

Data Submission

Award Information

In vitro human model for individualized response to CFTR modulators

Award Number: R41HL130207

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/06/2016

PERIOD OF PERFORMANCE END DATE: 08/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer